Rezolute (RZLT) Receivables - Notes (2012 - 2013)
Rezolute (RZLT) posted Receivables - Notes of $163829.0 for Q1 2013, down 80.32% sequentially from $832454.0 in Q2 2012.
Rezolute (RZLT) Receivables - Notes (2012 - 2013) Analysis & Trends
Rezolute has reported Receivables - Notes for 2 years, with the latest figure at $163829.0 in Q1 2013.
- Quarterly Receivables - Notes changed N/A year-over-year to $163829.0 in Q1 2013, while the trailing twelve-month figure through Mar 2013 was $163829.0 (changed N/A YoY) and the FY2012 annual result came in at $832454.0, changed N/A from the prior year.
- Receivables - Notes retreated to $163829.0 in Q1 2013 per RZLT's latest filing, from $832454.0 in the prior quarter.
- Over five years, Receivables - Notes peaked at $832454.0 in Q2 2012 and troughed at $163829.0 in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rezolute | 442.94 Mn | 442.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 163,829.00 |
| Jun 30, 2012 | 832,454.00 |